heptanoic acids

Summary

Summary: 7-carbon saturated monocarboxylic acids.

Top Publications

  1. ncbi Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, NY 11203, USA
    N Engl J Med 352:1425-35. 2005
  2. ncbi Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1495-504. 2004
  3. ncbi Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 352:29-38. 2005
  4. ncbi Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial
    Giuseppe Patti
    Department of Cardiovascular Sciences, Campus Bio Medico University, Rome, Italy
    J Am Coll Cardiol 49:1272-8. 2007
  5. ncbi Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Helen M Colhoun
    EURODIAB, Department of Epidemiology and Public Health, Royal Free and University College Medical School, London, UK
    Lancet 364:685-96. 2004
  6. ncbi Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease
    M Vasa
    Division of Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Theodor-Stern-Kai 7, Frankfurt, Germany
    Circulation 103:2885-90. 2001
  7. pmc Genome-wide association of lipid-lowering response to statins in combined study populations
    Mathew J Barber
    Department of Human Genetics, University of Chicago, Chicago, Illinois, United States of America
    PLoS ONE 5:e9763. 2010
  8. ncbi Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, G31 2ER, UK
    Clin J Am Soc Nephrol 2:1131-9. 2007
  9. ncbi Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway
    Bo Kyung Son
    Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan
    Circ Res 98:1024-31. 2006
  10. ncbi Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)
    Prakash Deedwania
    UCSF School of Medicine, San Francisco, Calif, USA
    Circulation 115:700-7. 2007

Research Grants

  1. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
  2. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
  3. Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
    Gregory Schwartz; Fiscal Year: 2008
  4. Osteoblastogenesis in Aortic Valve Calcification
    Nalini Rajamannan; Fiscal Year: 2006
  5. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 2002
  6. Physiogenomic Arrays for Clinical Neuropsychiatry
    GUALBERTO RUANO; Fiscal Year: 2006
  7. AMPHETAMINE ENHANCED STROKE RECOVERY--BURKE SRCI GROUP
    Larry Goldstein; Fiscal Year: 2002
  8. Biomarkers and Outcomes in the Diabetes Prevention Program
    Ronald B Goldberg; Fiscal Year: 2010
  9. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2002
  10. NUTRITION ACADEMIC AWARD
    Robert Knopp; Fiscal Year: 2002

Detail Information

Publications293 found, 100 shown here

  1. ncbi Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, NY 11203, USA
    N Engl J Med 352:1425-35. 2005
    ..We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD)...
  2. ncbi Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1495-504. 2004
    ..Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear...
  3. ncbi Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 352:29-38. 2005
    ..Intensive treatment produced greater reductions in both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP), suggesting a relationship between these two biomarkers and disease progression...
  4. ncbi Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial
    Giuseppe Patti
    Department of Cardiovascular Sciences, Campus Bio Medico University, Rome, Italy
    J Am Coll Cardiol 49:1272-8. 2007
    ..This study sought to investigate potential protective effects of atorvastatin in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI)...
  5. ncbi Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Helen M Colhoun
    EURODIAB, Department of Epidemiology and Public Health, Royal Free and University College Medical School, London, UK
    Lancet 364:685-96. 2004
    ..We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol...
  6. ncbi Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease
    M Vasa
    Division of Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Theodor-Stern-Kai 7, Frankfurt, Germany
    Circulation 103:2885-90. 2001
    ..Given the well-established role of EPCs of participating in repair after ischemic injury, stimulation of EPCs by statins may contribute to the clinical benefit of statin therapy in patients with CAD...
  7. pmc Genome-wide association of lipid-lowering response to statins in combined study populations
    Mathew J Barber
    Department of Human Genetics, University of Chicago, Chicago, Illinois, United States of America
    PLoS ONE 5:e9763. 2010
    ..To identify single nucleotide polymorphisms (SNPs) contributing to this variation, we performed a combined analysis of genome-wide association (GWA) results from three trials of statin efficacy...
  8. ncbi Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, G31 2ER, UK
    Clin J Am Soc Nephrol 2:1131-9. 2007
    ..This subanalysis of the Treating to New Targets study investigated how intensive lipid lowering with 80 mg of atorvastatin affects renal function when compared with 10 mg in patients with coronary heart disease...
  9. ncbi Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway
    Bo Kyung Son
    Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan
    Circ Res 98:1024-31. 2006
    ..These data demonstrate that statins protected HASMC from Pi-induced calcification by inhibiting apoptosis via restoration of the Gas6-Axl pathway...
  10. ncbi Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)
    Prakash Deedwania
    UCSF School of Medicine, San Francisco, Calif, USA
    Circulation 115:700-7. 2007
    ..However, no studies to date have assessed intensive versus moderate statin therapy in older patients with stable coronary syndromes...
  11. ncbi C-reactive protein levels and outcomes after statin therapy
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 352:20-8. 2005
    ..Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown...
  12. ncbi Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells
    Flore Mulhaupt
    Cardiology Division, Department of Medicine, University Hospital, Geneva Medical School, Foundation for Medical Research, 64 Avenue Roseraie, 1211 Geneva 4, Switzerland
    Cardiovasc Res 59:755-66. 2003
    ....
  13. ncbi Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
    Moran Boimel
    Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    J Neuropathol Exp Neurol 68:314-25. 2009
    ..Statins may provide therapy against NFTs in tauopathies, particularly when NFTs are the major neuropathologic component...
  14. ncbi Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
    Holly E Careskey
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Lipid Res 49:394-8. 2008
    ..These results suggest that the addition of a PCSK9 inhibitor to statin therapy may result in even further LDL-C decreases...
  15. pmc Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model
    Jean Baptiste Souraud
    Unite de Parasitologie, Unité de recherche sur les maladies infectieuses et transmissibles émergentes UMR 6236, Institut de Recherche Biomédicale des Armées Antenne de Marseille, Allée du Médecin Colonel Jamot, Parc le Pharo, BP 60109, 13262 Marseille Cedex 7, France
    Malar J 11:13. 2012
    ..Statins are recognized to have an immunomodulatory action, attenuate sepsis and have a neuroprotective effect. Atorvastatin (AVA) has shown in vitro anti-malarial activity and has improved the activity of mefloquine (MQ) and quinine...
  16. ncbi Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure
    Xiang Cheng
    Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
    J Card Fail 15:158-62. 2009
    ..The T-helper (Th)1/Th2 imbalance has been demonstrated to be involved in chronic heart failure (CHF). We sought to determine whether atorvastatin exhibited any effect on CHF through modulating the Th1/Th2 response...
  17. ncbi Assessment of the efficacy of different statins in murine collagen-induced arthritis
    Gaby Palmer
    University Hospital and University of Geneva School of Medicine, Geneva, Switzerland
    Arthritis Rheum 50:4051-9. 2004
    ..The aim of this study was to further investigate in vivo effects of 3 different statins, atorvastatin, rosuvastatin, and simvastatin, using the same experimental model...
  18. ncbi Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study
    Ana María Wagner
    Endocrinology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Diabetes Res Clin Pract 93:e25-8. 2011
    ..Both lipid-lowering drugs had positive, complementary and additive effects on inflammatory markers, which were closely related to baseline inflammatory status...
  19. ncbi High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial
    Hannu Päivä
    Department of Internal Medicine, University Hospital of Tampere, Finland
    Clin Pharmacol Ther 78:60-8. 2005
    ..This study was designed to assess the effect of high-dose statin treatment on cholesterol and ubiquinone metabolism and mitochondrial function in human skeletal muscle...
  20. ncbi High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study
    Scott Kinlay
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:1560-6. 2003
    ..Although statins reduce inflammatory markers in asymptomatic adults or in patients with stable angina, the effect of statins on the markedly heightened inflammation in patients with acute coronary syndromes is unknown...
  21. pmc Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum
    Véronique Parquet
    Unité de Recherche en Biologie et Epidémiologie Parasitaires Unité de Recherche pour les Maladies Infectieuses et Tropicales Emergentes UMR 6236, Institut de Medecine Tropicale du Service de Sante des Armees, Marseille, France
    Malar J 9:139. 2010
    ....
  22. pmc Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage
    Zacharie Taoufiq
    INSERM, UMR S945, Universite Pierre et Marie Curie Paris 6, CHU Pitie Salpetriere, 91 Bd de l Hopital, 75013 Paris, France
    Malar J 10:52. 2011
    ..Atorvastatin, a drug that belongs to the lowering cholesterol molecule family of statins, has been shown to ameliorate endothelial functions and is widely used in patients with cardiovascular disorders...
  23. ncbi Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan
    Takafumi Hiro
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan
    J Am Coll Cardiol 54:293-302. 2009
    ....
  24. ncbi Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
    Peter S Sever
    Imperial College, London, UK
    Lancet 361:1149-58. 2003
    ..No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemic...
  25. ncbi Toxicity of statins on rat skeletal muscle mitochondria
    P Kaufmann
    Division of Clinical Pharmacology and Toxicology and Department of Research, University Hospital, 4031, Basel, Switzerland
    Cell Mol Life Sci 63:2415-25. 2006
    ..Lipophilic statins impair the function of skeletal muscle mitochondria, whereas the hydrophilic pravastatin is significantly less toxic...
  26. ncbi Double-edged role of statins in angiogenesis signaling
    Carmen Urbich
    Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Frankfurt, Germany
    Circ Res 90:737-44. 2002
    ....
  27. pmc Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury
    Dunyue Lu
    Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan 48202, USA
    J Neurotrauma 24:1132-46. 2007
    ..These results suggest that statins may be candidates for treatment of TBI...
  28. ncbi Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study
    Olga A Iakoubova
    Celera, Alameda, California 9450, USA
    J Am Coll Cardiol 51:449-55. 2008
    ..We explored whether the benefit of intensive versus moderate statin therapy would be greater in carriers of KIF6 719Arg than in noncarriers...
  29. ncbi Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
    Christoph Wanner
    Division of Nephrology, Department of Medicine, University of Wurzburg, Wurzburg, Germany
    N Engl J Med 353:238-48. 2005
    ..However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined...
  30. pmc Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
    Jorie Versmissen
    Department of Internal Medicine, Erasmus University Medical Centre, PO Box 2040, 3000 CA Rotterdam, Netherlands
    BMJ 337:a2423. 2008
    ..To determine the efficacy of statin treatment on risk of coronary heart disease in patients with familial hypercholesterolaemia...
  31. ncbi Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients
    Connie Newman
    Pfizer Global Pharmaceuticals, New York, New York, USA
    Am J Cardiol 97:61-7. 2006
    ..In conclusion, the results of this analysis support the positive safety profile of atorvastatin at the highest dose...
  32. ncbi More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study
    Hidenori Arai
    Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
    J Atheroscler Thromb 17:1096-107. 2010
    ..The purpose of this study was to address the association of lipid levels after statin therapy with regression of atherosclerotic coronary lesions and major cardiovascular events in patients after ACS...
  33. ncbi Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study
    L B Goldstein
    Duke University Medical Center, Durham, NC 27710, USA
    Neurology 70:2364-70. 2008
    ..Post hoc analysis found this overall benefit included an increase in the numbers of treated patients having hemorrhagic stroke (n = 55 for active treatment vs n = 33 for placebo)...
  34. ncbi Lupus Atherosclerosis Prevention Study (LAPS)
    M A Petri
    Professor of Medicine, Johns Hopkins University, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA
    Ann Rheum Dis 70:760-5. 2011
    ..A study was undertaken to investigate whether treatment with statins would reduce subclinical measures of atherosclerosis over a 2-year period...
  35. ncbi Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial
    G G Schwartz
    Cardiology Section 111B, Denver VA Medical Center, 1055 Clermont St, Denver, CO 80220, USA
    JAMA 285:1711-8. 2001
    ....
  36. ncbi Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease
    Torgun Waehre
    Research Institute of Internal Medicine, Department of Cardiology, Rikshospitalet University Hospital, Oslo, Norway
    J Am Coll Cardiol 41:1460-7. 2003
    ..We sought to investigate whether the activation of the chemokine network observed in patients with coronary artery disease (CAD) could be modified by treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)...
  37. ncbi Growth inhibition of Candida species and Aspergillus fumigatus by statins
    Ian G Macreadie
    CSIRO Health and Molecular and Technologies and P Health Flagship, Parkville, Vic, Australia
    FEMS Microbiol Lett 262:9-13. 2006
    ..Our findings suggest that the statins could have utility as antifungal agents and that fungal colonization could be affected in those on statin therapy...
  38. ncbi Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study
    Vincenzo Pasceri
    Interventional Cardiology Unit, San Filippo Neri Hospital, Rome, Italy
    Circulation 110:674-8. 2004
    ..Observational studies have suggested that statins may lower the risk of procedural myocardial injury. The aim of our study was to confirm this hypothesis in a randomized study...
  39. ncbi Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 291:1071-80. 2004
    ..Statin drugs reduce both atherogenic lipoproteins and cardiovascular morbidity and mortality. However, the optimal strategy and target level for lipid reduction remain uncertain...
  40. pmc Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway
    Nalini M Rajamannan
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Circulation 112:I229-34. 2005
    ..We hypothesize that Lrp5 also plays a role in aortic valve (AV) calcification in experimental hypercholesterolemia...
  41. pmc SDF-1α upregulation by atorvastatin in rats with acute myocardial infarction via nitric oxide production confers anti-inflammatory and anti-apoptotic effects
    Ruofeng Qiu
    Department of Cardiology, the First Affiliated Hospital of Sun Yat Sen University, 58 Zhongshan Road 2, Guangzhou, 510080, China
    J Biomed Sci 19:99. 2012
    ..Therefore, our present study is to investigate the roles and mechanisms of atorvastatin treatment on SDF-1α expression in rats with AMI...
  42. ncbi Three-dimensional ultrasound quantification of intensive statin treatment of carotid atherosclerosis
    Adam Krasinski
    Imaging Research Laboratories, Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada N6A 5K8
    Ultrasound Med Biol 35:1763-72. 2009
    ..Quantitative VWV thickness difference maps provide visual evidence of the spatial and temporal dynamics of carotid artery changes...
  43. pmc Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease
    Olof Grip
    Division of Gastroenterology and Hepatology, Department of Clinical Sciences Malmo, Lund University, University Hospital MAS, Malmo, Sweden
    PLoS ONE 4:e5263. 2009
    ..Because statins can reduce chemokine expression in patients with coronary diseases, we wanted to test whether this can be achieved in patients with Crohn's disease...
  44. ncbi Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability
    Marika Massaro
    CNR Institute of Clinical Physiology, Pisa and Lecce, Italy
    Cardiovasc Res 86:311-20. 2010
    ..Because statins interfere with Rho activation, we investigated the statin effect on COX-2 and MMP expressions in the human endothelium...
  45. ncbi Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis
    C A C X Medeiros
    Department of Biomedical Sciences, State University of Rio Grande do Norte, Mossoró, Brazil
    Cancer Chemother Pharmacol 67:1085-100. 2011
    ..Oral mucositis (OM) is a frequent side effect in patients with cancer. We investigate the effect of atorvastatin (ATV), a cholesterol-lowering drug, on OM induced by 5-fluorouracil (5-FU) in hamsters...
  46. ncbi Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy
    Roberta Lanzillo
    Federico University, Neurological Sciences Department, Naples, Italy
    Mult Scler 16:450-4. 2010
    ..At survival analysis, the risk for a 1-point EDSS increase was slightly higher in group B than in group A (p = 0.053). Low-dose atorvastatin may be beneficial, as add-on therapy, in poor responders to high-dose interferon beta-1a alone...
  47. ncbi Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1
    Jie Chen
    State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University and Institute of System Biomedicine, Peking University, Beijing 100191, China
    Int J Biochem Cell Biol 44:759-69. 2012
    ..A combination of atorvastatin and carboplatin may be an effective strategy in clinical therapy against NSCLCs...
  48. ncbi Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
    A Asberg
    Medical Department, The National Hospital, Oslo, Norway
    Am J Transplant 1:382-6. 2001
    ..0% (p < 0.0001), respectively. Bilateral pharmacokinetic interaction between atorvastatin and CsA resulted in sixfold higher plasma HMG-CoA reductase inhibitory activity, but only a moderate decrease in systemic exposure of CsA...
  49. ncbi Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
    A S Brown
    Midwest Heart Research Foundation, Naperville, Illinois, USA
    J Am Coll Cardiol 32:665-72. 1998
    ..S. National Cholesterol Education Program (NCEP) recommended low-density-lipoprotein (LDL) cholesterol concentration (< or = 100 mg/dl [2.59 mmol/liter])...
  50. ncbi Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice
    Xi Zheng
    Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, The State University of New Jersey, Piscataway, New Jersey 08854, USA
    Clin Cancer Res 13:5480-7. 2007
    ..To investigate the effects and mechanisms of atorvastatin and celecoxib administered individually or in combination on human prostate cancer PC-3 cells cultured in vitro or grown as xenograft tumors in immunodeficient mice...
  51. ncbi Comparison of preventive effect on cardiovascular events with different statins. -The CIRCLE study-
    Takao Maruyama
    Department of Cardiology, Kawasaki Hospital, Kobe, Japan
    Circ J 75:1951-9. 2011
    ..Our objective was to compare the efficacy of statins on serum lipid levels and to explore the association between those changes and cardiac events in patients after percutaneous coronary intervention (PCI)...
  52. ncbi Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin
    O Ulicna
    Pharmacobiochemical Laboratory of Third Department of Internal Medicine, Comenius University, Bratislava, Slovak Republic
    Physiol Res 61:185-93. 2012
    ..This fact may play a significant role in the development of statin-induced hepatopathy...
  53. ncbi Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells
    S Morikawa
    Department of Molecular Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Meguro, Japan
    J Atheroscler Thromb 7:138-44. 2000
    ..NK-104 is most effective in inducing LDL receptor mRNA in Hep G2 cells...
  54. ncbi Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention
    Hang Xiao
    Department of Food Science, University of Massachusetts, Amherst, MA 01003, USA
    Int J Cancer 123:983-90. 2008
    ..This article reviews the evidence for the cancer preventive actions of statins and NSAIDs, as well as their possible synergistic action and the mechanisms involved...
  55. ncbi HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species
    S Wassmann
    Medizinische Klinik und Poliklinik, Innere Medizin III, , Hamburg/Saar, Germany
    Hypertension 37:1450-7. 2001
    ....
  56. ncbi Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke
    Jieli Chen
    Department of Neurology, Henry Ford Health Sciences Center, Detroit, MI 48202, USA
    Ann Neurol 53:743-51. 2003
    ..Atorvastatin also induced phosphorylation of Akt and Erk in cultured primary cortical neurons. These data indicate that atorvastatin induced brain plasticity and has neurorestorative activity after experimental stroke...
  57. ncbi Efficacy of Atorvastatin combined with adipose-derived mesenchymal stem cell transplantation on cardiac function in rats with acute myocardial infarction
    Anping Cai
    Department of Cardiology, the First Affiliated Hospital of Sun Yat Sen University, Guangzhou 510080, China
    Acta Biochim Biophys Sin (Shanghai) 43:857-66. 2011
    ..05). Pre-amelioration of the cardiac milieu, in conjunction with pre-specification of ASCs, was beneficial for enhancing ASCs' therapeutic efficacy on cardiac function after AMI...
  58. ncbi Effect of statin therapy on serum trace element status in dyslipidaemic subjects
    Majid Ghayour-Mobarhan
    Centre for Clinical Science and Measurement, School of Biomedical and Molecular Science, University of Surrey, Guildford, Surrey GU2 7XH, UK
    J Trace Elem Med Biol 19:61-7. 2005
    ..05) in either statin or control groups. These changes may be related to the known anti-inflammatory properties of the statin class of drugs...
  59. ncbi High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
    Terje R Pedersen
    Centre for Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    JAMA 294:2437-45. 2005
    ..Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery disease...
  60. ncbi Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients
    David Guillen
    Pharmacology Laboratory Biomedical Diagnosis Center, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Mol Diagn Ther 14:357-66. 2010
    ..However, the role of statins in the immunosuppressive response that is achieved in individual patients remains to be assessed...
  61. pmc Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction
    Matthew E Gegg
    Division of Cellular Therapy, Institute of Ophthalmology, University College London, London, United Kingdom
    J Immunol 174:2327-35. 2005
    ..These data highlight the potential differential activity of statins in different inflammatory conditions and their possible therapeutic use for the treatment of human posterior uveitis...
  62. pmc Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS)
    Shaun G Goodman
    St Michael s Hospital and University of Toronto, Toronto, Ontario
    Can J Cardiol 26:e330-5. 2010
    ..Despite clear guideline recommendations, there is a growing body of evidence that there is suboptimal use of lipid-lowering treatment in Canadians...
  63. pmc Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin
    Orhan Aktas
    Institute of Neuroimmunology, Neuroscience Research Center, NWFZ 2680, Charite, 10098 Berlin, Germany
    J Exp Med 197:725-33. 2003
    ..However, early T cell activation was unaffected, as reflected by unaltered calcium fluxes. Thus, our results provide evidence for a beneficial role of statins in the treatment of autoimmune attack on the CNS...
  64. ncbi Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients
    Kaan Tunceli
    Global Health Outcomes, Merck, Whitehouse Station, NJ 08889 0100, USA
    J Clin Lipidol 4:491-500. 2010
    ..The availability of generic simvastatin in 2006 has prompted substantial changes in formulary recommendations for lipid-management agents...
  65. ncbi Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial
    C Hernandez
    CIBER de Diabetes y Enfermedades Metabólicas Asociadas CIBERDEM, Barcelona, Spain
    Diabetes Metab 37:124-30. 2011
    ..This study aimed to determine the effect of atorvastatin therapy on plasma lipoprotein (a) [Lp(a)] and biomarkers of inflammation in hypercholesterolaemic patients free of cardiovascular disease...
  66. ncbi Combination of amlodipine and atorvastatin synergistically reduces leukocyte recruitment to mechanically injured mouse femoral artery
    Sumihiko Hagita
    Life Science and Bioethics Research Center, Tokyo Medical and Dental University, Tokyo, Japan
    Hypertens Res 34:450-5. 2011
    ..The underlying mechanisms of their effect involve, at least in part, stabilizing oxidative stress at the point of injury, suggesting the clinical efficacy of this drug combination for the treatment of vascular diseases...
  67. ncbi Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings
    B Sönmez Uydeş-Doğan
    Istanbul University Faculty of Pharmacy, Department of Pharmacology, 34116, Beyazit, Istanbul, Turkey
    Life Sci 76:1771-86. 2005
    ..Our findings suggest that statins could acutely modulate vascular tone importantly by endothelium-dependent and mevalonate-related pathways...
  68. ncbi Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease
    Barbara A Evans
    Proteomics and Mass Spectrometry Facility, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Dement Geriatr Cogn Disord 27:519-24. 2009
    ..Our aim was to assess changes in brain cholesterol metabolism as reflected in the cerebrospinal fluid (CSF) before and after treatment with either atorvastatin or simvastatin...
  69. ncbi Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin
    Salvatore Rosanio
    The Department of Internal Medicine, Division of Cardiology, The University of Texas Medical Branch UTMB, Galveston, TX 77555, USA
    Cardiovasc Drugs Ther 20:27-36. 2006
    ..We investigated whether atorvastatin (ATV) and sildenafil (SL) have synergistic effects on myocardial infarct size (IS) reduction and enhancing nitric oxide synthase (NOS) expression...
  70. pmc Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia
    Neel R Sodha
    Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Card Surg 23:312-20. 2008
    ..We sought to determine if atorvastatin modulates oxidative stress in myocardial tissue...
  71. pmc Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors
    M Maczewski
    Department of Clinical Physiology, Medical Center of Postgraduate Education, Warsaw, Poland
    Br J Pharmacol 154:1640-8. 2008
    ..This study examined whether worsening of post-MI ventricular remodelling induced by dietary hypercholesterolaemia was related to upregulation of angiotensin II type 1 (AT1) receptor in the rat heart...
  72. ncbi Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver
    Montserrat Moreno
    Institut de Malalties Digestives i Metaboliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigación Biomédica Esther Koplowitz, Barcelona, Catalonia, Spain
    Am J Physiol Gastrointest Liver Physiol 296:G147-56. 2009
    ..These results indicate that atorvastatin attenuates the pathogenic events induced by ANG II in the liver both in vivo and in vitro. Therefore, statins could have beneficial effects in conditions characterized by hepatic inflammation...
  73. ncbi Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study
    Mark S Kipnes
    DGD Research a Cetero research company, San Antonio, Texas, USA
    Clin Drug Investig 30:51-61. 2010
    ..This year 2 study evaluated fenofibric acid 135 mg in combination with moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg or atorvastatin 40 mg) in patients with mixed dyslipidaemia...
  74. ncbi Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia
    Peter H Jones
    Baylor College of Medicine, Houston, TX 77030, USA
    Am Heart J 160:759-66. 2010
    ..Statin and ezetimibe combination therapy may be insufficient to improve lipid and nonlipid parameters beyond low-density lipoprotein cholesterol (LDL-C) in patients with mixed dyslipidemia...
  75. ncbi Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats
    Nuria Roglans
    Unidad de Farmacología y Farmacognosia, Facultad de Farmacia, Universidad de Barcelona, Avenida Diagonal 643, 08028 Barcelona, Spain
    J Pharmacol Exp Ther 302:232-9. 2002
    ..The increase in PPARalpha expression caused by atorvastatin was associated with reduced liver triglyceride and plasma NEFA levels...
  76. ncbi Safety of HMG-CoA reductase inhibitors: focus on atorvastatin
    F Bernini
    Department of Pharmacological Sciences, University of Milano, Italy
    Cardiovasc Drugs Ther 15:211-8. 2001
    ..Atorvastatin is well tolerated in long-term treatment of dyslipidemia and is characterized by a safety profile similar to the other available statins...
  77. ncbi Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease
    Kensuke Toyama
    Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
    Atherosclerosis 217:158-64. 2011
    ..We compared the effects of two statins (rosuvastatin and atorvastatin) combined with exercise on coenzyme Q10 and HDL-C levels in CAD patients...
  78. ncbi Statins attenuate high mobility group box-1 protein induced vascular endothelial activation : a key role for TLR4/NF-κB signaling pathway
    Jun Yang
    Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China
    Mol Cell Biochem 345:189-95. 2010
    ..The underlying mechanism involves, at least in part, inhibition of TLR4/NF-κB-dependent signaling pathway, which provied the new evidence for therapeutic application of statins to target inflammatory processes in cardiovascular disease...
  79. ncbi 3D ultrasound measurement of change in carotid plaque volume: a tool for rapid evaluation of new therapies
    Craig D Ainsworth
    Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, 1400 Western Rd, London, ON, N6G 2V2, Canada
    Stroke 36:1904-9. 2005
    ..To study such treatments, it will be necessary to directly measure changes in atherosclerosis. The study was designed to determine sample sizes needed to detect effects of treatment using 3D ultrasound (US) measurement of carotid plaque...
  80. ncbi Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
    Jennifer G Robinson
    University of Iowa College of Public Health, Iowa City, Iowa, USA
    Am J Cardiol 103:1694-702. 2009
    ..In conclusion, ezetimibe/simvastatin was more likely to result in lipid treatment end points than atorvastatin and was generally well tolerated at the doses compared in our patients...
  81. pmc Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy
    Vinitha Senthil
    Department of Medicine, Baylor College of Medicine, One Baylor Plaza, 519D, Houston, TX 77030, USA
    Circ Res 97:285-92. 2005
    ..The results indicate potential beneficial effects of atorvastatin in prevention of cardiac hypertrophy, a major determinant of morbidity in all forms of cardiovascular diseases, and beckon clinical studies in humans with HCM...
  82. pmc Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-gamma in HaCaT cells, a human keratinocyte cell line
    Xu Feng Qi
    Department of Environmental Medical Biology, Wonju College of Medicine, Yonsei University, Wonju, Gangwon, Korea
    Br J Pharmacol 157:1441-50. 2009
    ..This study aimed to define how different statins affect MDC expression in HaCaT cells, a human keratinocyte cell line...
  83. pmc Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction
    Xian Liang Tang
    Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America
    PLoS ONE 6:e25320. 2011
    ..These salubrious effects may be due in part to a decrease in myocardial fibrosis and apoptosis...
  84. ncbi Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors
    Terry A Jacobson
    Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30303, USA
    Am J Cardiol 94:1140-6. 2004
    ..Pravastatin has a neutral drug interaction profile relative to cytochrome P450-3A4 inhibitors, but these substrates markedly increase systemic exposure to simvastatin and atorvastatin...
  85. pmc Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis
    Ting Ting Tang
    Laboratory of Cardiovascular Immunology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China
    J Lipid Res 52:1023-32. 2011
    ..In conclusion, AT significantly increased T(reg) numbers and restored their suppressive function in the RA patients, and this may be relevant in the modulation of uncontrolled inflammation in this disorder...
  86. ncbi Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels
    Angelo M Scanu
    Department of Medicine, University of Chicago, Illinois 60637, USA
    Lipids 37:439-44. 2002
    ..We conclude that true LDL but not Lp(a) cholesterol is affected by statin therapy and that this specific response cannot be monitored by current LDL cholesterol assays and must, rather, rely on estimates of these two analytes...
  87. pmc HMG-CoA reductase inhibitors and P-glycoprotein modulation
    K Bogman
    Department of Clinical Pharmacology and Toxicology, University Hospital/Kantonsspital, Basel, Switzerland
    Br J Pharmacol 132:1183-92. 2001
    ....
  88. ncbi Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin
    B A Schick
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, and Research Unit, Tampere University Hospital, Finland
    Clin Pharmacol Ther 81:650-3. 2007
    ..We retrospectively quantified mtDNA in 86 skeletal muscle biopsy specimens collected as part of a previously published clinical trial of high-dose simvastatin or atorvastatin versus placebo...
  89. ncbi Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure
    Srikanth Sola
    Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia 30303, USA
    J Am Coll Cardiol 47:332-7. 2006
    ..This study examined the effect of statin therapy on vascular markers of inflammation and echocardiographic findings in patients with nonischemic forms of cardiomyopathy...
  90. ncbi Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study
    Seung Hyuk Choi
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Am Coll Cardiol 52:24-32. 2008
    ..This study was designed to test the hypothesis that circulating biomarkers of oxidized low-density lipoprotein (OxLDL) are affected by statin therapy and predict changes in atheroma volume...
  91. ncbi High-dose atorvastatin after stroke or transient ischemic attack
    Pierre Amarenco
    Denis Diderot University, Paris
    N Engl J Med 355:549-59. 2006
    ..Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established...
  92. ncbi Cellular antioxidant effects of atorvastatin in vitro and in vivo
    Sven Wassmann
    Medizinische Klinik und Poliklinik Innere Medizin III, Universitatskliniken des Saarlandes, Homburg Saar, Germany
    Arterioscler Thromb Vasc Biol 22:300-5. 2002
    ..These effects of atorvastatin may contribute to the vasoprotective effects of statins...
  93. ncbi HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes
    Birgit Assmus
    Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Frankfurt, Germany
    Circ Res 92:1049-55. 2003
    ..The inhibition of EPC senescence and induction of EPC proliferation by statins in vitro may importantly improve the functional activity of EPCs for potential cell therapy...
  94. ncbi Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma
    E J Hothersall
    Respiratory Medicine Section, Division of Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK
    Thorax 63:1070-5. 2008
    ..A study was undertaken to test the hypothesis that atorvastatin added to inhaled corticosteroids improves lung function and airway inflammation in atopic adults with asthma...
  95. ncbi Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
    Prakash Deedwania
    Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine, San Francisco, CA, USA
    Lancet 368:919-28. 2006
    ....
  96. ncbi Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 54:2290-5. 2009
    ....
  97. ncbi Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort
    John F Thompson
    Helicos BioSciences, Cambridge, MA, USA
    Circ Cardiovasc Genet 2:173-81. 2009
    ..To address this, 5745 individuals from the Treating to New Targets (TNT) trial were genotyped in a combination of a whole-genome and candidate gene approach to identify associations with response to atorvastatin treatment...
  98. ncbi UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo
    S Riedmaier
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 87:65-73. 2010
    ..The potential of UGT genotyping to identify patients who are at increased risk for failure of therapy and/or adverse effects of statins warrants further investigation...
  99. ncbi Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes
    Stuart W Paine
    Department of Discovery Drug Metabolism and Pharmacokinetics, AstraZeneca R and D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH, United Kingdom
    Drug Metab Dispos 36:1365-74. 2008
    ....
  100. ncbi Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase
    S Wassmann
    Medizinische Klinik und Poliklinik, Innere Medizin III, , Homburg/Saar, Germany
    Mol Pharmacol 59:646-54. 2001
    ....
  101. ncbi Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1
    Cuiping Chen
    Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, MS4044, Eastern Point Rd, Groton, CT 06340, USA
    Drug Metab Dispos 33:537-46. 2005
    ....

Research Grants63

  1. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
    ....
  2. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  3. Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
    Gregory Schwartz; Fiscal Year: 2008
    ..Therefore, an additional goal is to determine whether chronic treatment with a PPAR alpha or gamma agonist modifies myocardial metabolic and contractile dysfunction after I/R in insulin resistant pigs. ..
  4. Osteoblastogenesis in Aortic Valve Calcification
    Nalini Rajamannan; Fiscal Year: 2006
    ..If hypercholesterolemia stimulates the development of calcification in the aortic valve then the use of medical therapy such as HMG CoA reductase medications may have a role in the medical therapy of calcific aortic stenosis. ..
  5. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 2002
    ....
  6. Physiogenomic Arrays for Clinical Neuropsychiatry
    GUALBERTO RUANO; Fiscal Year: 2006
    ..The program will develop NeuroPsych Gene Array products as a new tool for systems understanding of neuropsychiatric and neurodegenerative diseases leading to early diagnosis and personalized therapy. [unreadable] [unreadable]..
  7. AMPHETAMINE ENHANCED STROKE RECOVERY--BURKE SRCI GROUP
    Larry Goldstein; Fiscal Year: 2002
    ..However the treatment duration will be increased to a total of 10 sessions. ..
  8. Biomarkers and Outcomes in the Diabetes Prevention Program
    Ronald B Goldberg; Fiscal Year: 2010
    ....
  9. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2002
    ....
  10. NUTRITION ACADEMIC AWARD
    Robert Knopp; Fiscal Year: 2002
    ..It is time to begin aggressive, substantive nutrition educational programs in cardiovascular disease prevention. ..
  11. Older Persons & Drugs: race, gender, and age effects
    JANICE SCHWARTZ; Fiscal Year: 2009
    ..The potential impact of these findings on the care of the growing number of very old patients, especially understudied women and minority groups, is great. ..
  12. Iron Therapy in Renal Disease: Potential Toxicities
    RICHARD ZAGER; Fiscal Year: 2008
    ..Potential reasons for these differences will be assessed, with the ultimate goal of defining the safest way of administering parenteral irons to renal disease patients. ..
  13. CAROTID PLAQUE COMPOSITION BY MRI DURING LIPID-LOWERING
    Xue Qiao Zhao; Fiscal Year: 2010
    ....
  14. DIETS FOR DYSLIPIDEMIA IN THE METABOLIC SYNDROME
    Robert Knopp; Fiscal Year: 2009
    ..This study will be the first to demonstrate dietary benefit for dyslipidemia, inflammation and vascular stress in MetS at stable weight. ..
  15. MIDCAREER INVESTIGATOR AWARD IN CEREBROVASCULAR RESEARCH
    Larry Goldstein; Fiscal Year: 2004
    ....
  16. CARDIAC VALVE CALCIFICATION
    Emile Mohler; Fiscal Year: 2003
    ..2. To investigate mechanisms of valve calcification using a cell culture model of calcification. 3. To examine therapeutic strategies to inhibit valve calcification with a bisphosphonate in cell culture. ..
  17. ACUTE RENAL FAILURE--IMPACT OF FLUORINATED ANESTHETICS
    RICHARD ZAGER; Fiscal Year: 2001
    ....
  18. International Network and Registry for TMA
    Howard Trachtman; Fiscal Year: 2007
    ..These include essential hypertension, diabetes, hyperlipidemia, myocardial infarction, and chronic kidney disease. [unreadable] [unreadable]..
  19. Neurorestorative Therapy of Stroke with Statins
    Jieli Chen; Fiscal Year: 2007
    ..This study provides a new and highly effective way to treat stroke and may permit translation our finding of restorative therapeutic benefit of statin in experimental stroke to the patient. ..
  20. Fatty Acids and Cardiovascular Health
    Dariush Mozaffarian; Fiscal Year: 2007
    ..End of Abstract) [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  21. Electro-Mechanical Micro-Post Array to Detect In Vitro Muscle Contraction
    Herman Vandenburgh; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  22. High Content Screening for Muscular Dystrophy
    Herman Vandenburgh; Fiscal Year: 2007
    ..While not a cure for the disease, these new drug therapies are aimed at enhancing quality and longevity of life of the DMD patient. [unreadable] [unreadable] [unreadable] [unreadable]..
  23. Clinical Utility of Endothelial Function in PAD
    Joseph Vita; Fiscal Year: 2007
    ..This work will provide novel information about the pathogenesis and management of PAD. ..
  24. Adult human skeletal muscle stem cells for functional repair
    Herman Vandenburgh; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  25. Pharmacokinetics & Genomics in Glomerular Diseases
    MELANIE JOY; Fiscal Year: 2008
    ..The selection of collaborators with expertise in the areas of this grant will enhance the career development of Dr. Joy. ..
  26. BIOLOGY OF PROTEOLYTIC DERIVATIVES OF LP(A)
    ANGELO SCANU; Fiscal Year: 2009
    ..The results of the proposed studies should shed light on whether ox-PL adducts play a role in the cardiovascular pathogenicity of Lp(a). ..
  27. The Effect of Statins on Skeletal Muscle Function
    PAUL DAVIS THOMPSON; Fiscal Year: 2010
    ....
  28. Adipocyte Lipid Metabolism and ApoE Expression
    Theodore Mazzone; Fiscal Year: 2009
    ..For these studies, adipose tissue will be collected from the gluteal and abdominal subcutaneous regions, and from the intraperitoneal visceral region, of patients undergoing bariatric surgery;and utilized for isolation of adipocytes. ..
  29. HDL metabolism: Influence of extracellular lipases
    Daniel Rader; Fiscal Year: 2009
    ....
  30. Molecular Epidemiology of Colorectal Cancer Subtypes
    Paul J Limburg; Fiscal Year: 2010
    ....
  31. Mechanisms of Atherosclerosis and CVD in HIV+ Women
    Robert Kaplan; Fiscal Year: 2009
    ..This investigation will have major implications for the development of strategies to predict, prevent, or reverse atherosclerosis in HIV- infected women. ..
  32. Electronic Diary Assessment of Pain in Juvenile Arthritis
    Laura E Schanberg; Fiscal Year: 2010
    ..Finally, the study can serve as a catalyst for future research aimed at advancing medical and psychological knowledge of pain in other pediatric medical populations. ..
  33. High Content Drug Screening with Cardiac Tissue
    Herman Vandenburgh; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  34. Determinants of Shear Stress-Mediated Arterial Remodeling
    Joseph Vita; Fiscal Year: 2009
    ....
  35. Mentored Career Development in Patient Oriented Research
    Daniel Rader; Fiscal Year: 2006
    ..abstract_text> ..
  36. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 2003
    ..The outcome of this trial may justify the use of SYNSORB PK as a safe therapy to ameliorate D+HUS. ..
  37. Regulation of APP Processing by Presenilins
    Benjamin Wolozin; Fiscal Year: 2004
    ..Identification of mutant forms of presenilin that inhibit beta- amyloid production could lead to novel strategies for therapeutic intervention in Alzheimer's disease. ..
  38. DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK
    ERNST SCHAEFER; Fiscal Year: 2003
    ..abstract_text> ..
  39. HIGH DENSITY LIPOPROTEIN SUBSPECIES AND CORONARY DISEASE
    Bela Asztalos; Fiscal Year: 2003
    ..The investigators state that these studies should provide better understanding about the diagnosis and treatment of HDL deficiency for the prevention of CHD. ..
  40. INTERACTIONS OF LP(A) WITH VASCULAR EXTRACELLULAR MATRIX
    ANGELO SCANU; Fiscal Year: 2002
    ..Underlying these studies is the hypothesis, that the MMP-mediated changes in Lp(a)/apo(a) are favored by the inflammatory milieu of the human atheroma. ..
  41. BABAA RECEPTORS IN AGING & ALZHEIMER'S DISEASE
    Samuel Gandy; Fiscal Year: 2002
    ....
  42. CELL SURFACE METABOLISM OF MACROPHAGE DERIVED APO E
    Theodore Mazzone; Fiscal Year: 2001
    ..In this Specific Aim we will more thoroughly examine the metabolism of LDL and ALDL as it is influenced by the cell surface pool of macrophage derived apo E. ..
  43. Fats, Immune Response and Atherosclerosis
    Ngoc Anh Le; Fiscal Year: 2002
    ..In summary, the researchers should be able to demonstrate and inverse relationship between autoantibody titers and disease severity in diet-induced atherosclerosis. ..
  44. TRANSMITTER NEUROANATOMY IN ALZHEIMERS DISEASE
    Samuel Gandy; Fiscal Year: 2002
    ....
  45. TISSUE ENGINEERED MYOFIBERS FOR GENE THERAPY
    Herman Vandenburgh; Fiscal Year: 2001
    ..S. health care market. ..
  46. CELLULAR BASIS OF ANTIATHEROGENESIS BY APOLIPOPROTEIN E
    Daniel Rader; Fiscal Year: 2001
    ..These studies will provide greater understanding of the role of the local inflammatory response in atherosclerosis and its regulation by apoE. ..
  47. PROTEASE INHIBITOR-INDUCED HYPERLIPIDEMIA IN AIDS
    Virgil Brown; Fiscal Year: 2004
    ..These are specific agents that are effective in reducing triglyceride as well as improving insulin resistance. ..
  48. Human monoclonal antibody therapy for HUS
    Howard Trachtman; Fiscal Year: 2004
    ..abstract_text> ..
  49. Revision of ACR Classification Criteria for Systemic Lupus Erythematosus
    Michelle Petri; Fiscal Year: 2007
    ..This project will lead to updated, validated SLE classification criteria that can be immediately used by both industry and academic clinical trials. ..
  50. Novel Therapies for Resistant FSGS
    Howard Trachtman; Fiscal Year: 2006
    ..The infrastructure that is established for the performance of this R21/R33 project should prove useful for the efficient assessment of additional novel therapies that will be developed in the future for patients with primary FSGS. ..
  51. Vascularization of Tissue Engineered Skeletal Muscle
    Herman Vandenburgh; Fiscal Year: 2006
    ..Successful completion of this project will allow the development of a reversible ex vivo gene therapy method to treat hemophilia A. [unreadable] [unreadable] [unreadable]..
  52. Mechanisms of Hawthorn Action in Heart Failure
    Barry Bleske; Fiscal Year: 2005
    ..The results from this study will have important translation to both the basic and clinical research settings. ..
  53. Lipid Testing /Treatment in Older MI Patients
    JoAnne Foody; Fiscal Year: 2005
    ..This work will ultimately improve care for the elderly patient with cardiovascular disease. ..
  54. Ubiquitination/Receptor Signaling--Regulation by Parkin
    Benjamin Wolozin; Fiscal Year: 2004
    ..abstract_text> ..
  55. Chemokines, nitric oxide, and myocardial depression
    Bysani Chandrasekar; Fiscal Year: 2005
    ..The results from these studies will further our knowledge of chemokine biology and lead to new therapeutic strategies to prevent or treat myocardial dysfunction in ischemia-reperfusion injury. ..
  56. Training CAM Clinical Investigators
    Richard Grimm; Fiscal Year: 2006
    ..Dr. Richard Grimm is Program Director. The Program will produce a highly trained cadre of clinical investigators with the knowledge and experience to becoming leading researchers in CAM. ..
  57. Lipitor/Celebrex: effect on prostate cancer progression
    Xi Zheng; Fiscal Year: 2007
    ..This combination of drugs may significantly improve the management of prostate cancer. [unreadable] [unreadable] [unreadable]..
  58. Headache Research Summit
    KENNETH WELCH; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  59. TRAINING A NEW GENERATION OF CAM CLINICAL INVESTIGATORS
    Richard Grimm; Fiscal Year: 2006
    ..abstract_text> ..
  60. Enhanced Prescription Drug Label Design to Improve Patient Understanding and Use
    Michael S Wolf; Fiscal Year: 2010
    ..This study will advance the science related to Rx labeling practices. Findings will directly inform clinical practice and state and federal policies for improving patient medication information and safety. ..
  61. Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect
    Richard Price; Fiscal Year: 2004
    ....
  62. CSF Molecular Marker Study Consortium
    Richard Price; Fiscal Year: 2006
    ..abstract_text> ..